{
  "trial_id": "NCT03463265",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, histologic evidence of high grade glioma, radiographic evidence of recurrence or disease progression, prior treatment regimen, prior use of mTOR inhibitors, prior use of temozolomide, prior use of bevacizumab or other anti-angiogenic agents, prior use of lomustine, prior use of marizomib or other proteasome inhibitors, time since surgical resection, time since end of radiotherapy, presence of measurable lesion by RANO criteria, history of thrombotic or hemorrhagic stroke, history of myocardial infarction, pregnancy status, presence of uncontrolled intercurrent illness, presence of active gastrointestinal bleeding, blood pressure levels, history of intestinal perforations, history of fistula, history of hemorrhages, history of hemoptysis, diabetes mellitus status, history of interstitial lung disease, history of pneumonitis, history of pulmonary hypertension, use of strong inhibitors and inducers of CYP3A4, use of known CYP3A4 substrates with narrow therapeutic window, history of other malignancies, comorbid conditions, HIV status, Hepatitis B status, Hepatitis C status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "histologic evidence of high grade glioma",
        "radiographic evidence of recurrence or disease progression",
        "prior treatment regimen",
        "prior use of mTOR inhibitors",
        "prior use of temozolomide",
        "prior use of bevacizumab or other anti-angiogenic agents",
        "prior use of lomustine",
        "prior use of marizomib or other proteasome inhibitors",
        "time since surgical resection",
        "time since end of radiotherapy",
        "presence of measurable lesion by RANO criteria",
        "history of thrombotic or hemorrhagic stroke",
        "history of myocardial infarction",
        "pregnancy status",
        "presence of uncontrolled intercurrent illness",
        "presence of active gastrointestinal bleeding",
        "blood pressure levels",
        "history of intestinal perforations",
        "history of fistula",
        "history of hemorrhages",
        "history of hemoptysis",
        "diabetes mellitus status",
        "history of interstitial lung disease",
        "history of pneumonitis",
        "history of pulmonary hypertension",
        "use of strong inhibitors and inducers of CYP3A4",
        "use of known CYP3A4 substrates with narrow therapeutic window",
        "history of other malignancies",
        "comorbid conditions",
        "HIV status",
        "Hepatitis B status",
        "Hepatitis C status"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Histologic Grade, Prior Treatment Regimen, Time Since Last Treatment, Measurable Lesion by RANO Criteria, Karnofsky Performance Status, Hemoglobin A1c, Systolic Blood Pressure, Diastolic Blood Pressure, ",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Histologic Grade",
        "Prior Treatment Regimen",
        "Time Since Last Treatment",
        "Measurable Lesion by RANO Criteria",
        "Karnofsky Performance Status",
        "Hemoglobin A1c",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Karnofsky Performance Status, Histological diagnosis, Tumor size, Number of prior therapies, Time from initial diagnosis, Time from last progression, Prior treatment with chemotherapy, Prior treatment with radiation therapy, Prior treatment with surgery, HbA1c, Blood pressure, Diabetes status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Karnofsky Performance Status",
        "Histological diagnosis",
        "Tumor size",
        "Number of prior therapies",
        "Time from initial diagnosis",
        "Time from last progression",
        "Prior treatment with chemotherapy",
        "Prior treatment with radiation therapy",
        "Prior treatment with surgery",
        "HbA1c",
        "Blood pressure",
        "Diabetes status."
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, Karnofsky Performance Status (KPS), Eastern Cooperative Oncology Group (ECOG) performance status, histologic diagnosis, WHO grade, number of prior therapies, time from initial diagnosis, time from prior therapy, presence of measurable disease, prior surgery, prior radiation therapy, prior chemotherapy, prior treatment with bevacizumab or other anti-angiogenic agents, prior treatment with mTOR inhibitors.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "Karnofsky Performance Status (KPS)",
        "Eastern Cooperative Oncology Group (ECOG) performance status",
        "histologic diagnosis",
        "WHO grade",
        "number of prior therapies",
        "time from initial diagnosis",
        "time from prior therapy",
        "presence of measurable disease",
        "prior surgery",
        "prior radiation therapy",
        "prior chemotherapy",
        "prior treatment with bevacizumab or other anti-angiogenic agents",
        "prior treatment with mTOR inhibitors."
      ]
    }
  }
}